NCT02802553
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Suspended
Not Applicable
Drug Category: Other

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have at least 1 lesion of tumor of the breast
Exclusions: Patients who have been treated with radiation therapy on the chest; Patients with previous sentinel lymph node biopsy
https://ClinicalTrials.gov/show/NCT02802553